European Urology Oncology Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy  Karl Patterson, Vimalanand Prabhu, Ruifeng Xu, Haojie Li, Yang Meng, Natalie Zarabi, Yichen Zhong, Rachael Batteson, James Pellissier, Stephen Keefe, Petros Grivas, Ronald de Wit  European Urology Oncology  DOI: 10.1016/j.euo.2018.09.009 Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

Fig. 1 Model structure. European Urology Oncology DOI: (10.1016/j.euo.2018.09.009) Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

Fig. 2 Kaplan-Meier (KM) and fitted survival curves. SOC=standard of care (gemcitabine plus carboplatin). European Urology Oncology DOI: (10.1016/j.euo.2018.09.009) Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

Fig. 3 One-way sensitivity analysis for pembrolizumab versus standard of care (SOC). AE=adverse event; ICER=incremental cost-effectiveness ratio; KN052=KEYNOTE-052; Lnormal=log-normal; OS=overall survival; PFS=progression-free survival. European Urology Oncology DOI: (10.1016/j.euo.2018.09.009) Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

Fig. 4 Cost-effectiveness acceptability curve. SOC=standard of care (carboplatin plus gemcitabine). European Urology Oncology DOI: (10.1016/j.euo.2018.09.009) Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions